Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218334

SCHEMBL23218334

SCHEMBL23218334

CCOC(=O)Cc1ccccc1OCc1coc2c(NC3CCCC3)cc(Cl)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ POLB P06746 2/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ RIN1 Q13671 1/20 0.37
▸ MAPT P10636 3/20 0.35
▸ CASP3 P42574 3/20 0.35
▸ TP53 P04637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TBXAS1 P24557 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ GPBAR1 Q8TDU6 1/20 0.33
▸ CFD P00746 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853092 1.00 ALOX15 (0.37) ALOX15TSHRHSD17B10MEN1KMT2A
SCHEMBL29593177 1.00 ALOX15 (0.37) ALOX15TSHRHSD17B10MEN1KMT2A
SCHEMBL29852426 0.89 PTGER4 (0.35) TSHRHSD17B10MEN1KMT2APOLB
SCHEMBL23219001 0.89 PTGER4 (0.35) TSHRHSD17B10MEN1KMT2APOLB
SCHEMBL29591282 0.89 PTGER4 (0.35) TSHRHSD17B10MEN1KMT2APOLB
SCHEMBL23218319 0.87 MAPT (0.39) MEN1KMT2AMAPTTP53THRB
SCHEMBL29591201 0.87 MAPT (0.39) MEN1KMT2AMAPTTP53THRB
SCHEMBL29853027 0.87 MAPT (0.39) MEN1KMT2AMAPTTP53THRB
SCHEMBL23218917 0.87 PTGER4 (0.38) MEN1KMT2APOLBMAPTTP53
SCHEMBL29852993 0.87 PTGER4 (0.38) MEN1KMT2APOLBMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ALOX15 224/4885TSHR 1199/4885HSD17B10 1149/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALOX15 276/4885TSHR 3148/4885HSD17B10 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.